Crossmark Global Holdings
AGMB icon

Crossmark Global Holdings’s AgomAb Therapeutics NV AGMB Stock Holding History

Crossmark Global Holdings’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$256K Buy
+23,096
New +$299K ﹤0.01% 1123

Other funds holding AGMB

Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Pinnacle Wealth Planning Services
Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Crossmark Global Holdings's AGMB Position: Q3 2026 in Review

Crossmark Global Holdings opened a new position in AgomAb Therapeutics NV (AGMB) in Q3 2026: 23,096 shares worth $256K. The stake represents ﹤0.01% of the portfolio and ranks #1123 among its holdings.

7 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Crossmark Global Holdings held 23,096 shares of AgomAb Therapeutics NV worth $256K as of Q3 2026.
  • AgomAb Therapeutics NV was a new Crossmark Global Holdings position in Q3 2026.
  • AgomAb Therapeutics NV made up ﹤0.01% of Crossmark Global Holdings's portfolio in Q3 2026, its #1123 holding.
  • 7 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Crossmark Global Holdings's 13F filing for Q3 2026, filed 21 Oct 2026.